Focus Groups Discussions:
- Part I (Challenges and Opportunities)
- Part II (Solutions & Action Items)
Drug Discovery & Development for Diabetes:
- Opening Keynote Session – Historical Perspective & State of the Science & Industry
- Type I Diabetes – Preclinical & Clinical Development
- Type II Diabetes – Preclinical & Clinical Development
- Devices & Digital Aids in Diabetes Management
Funding, Partnering & Commercialization of Diabetes Technologies:
- Industry Partnering with Academia & CROs to Advance Diabetes Research
- Funding & Commercialization of Diabetes Technologies
- Award Ceremony & Closing Keynote Session – Predictions for the Future
- Keynote Panel Discussion
|2018 Advisory Board Members|
|Robert Geho, Diasome Pharmaceuticals Inc|
|Zan Fleming, Kinexum|
|Alan Cherrington, Vanderbilt|
|Brian T. Bloomquist, Eli Lilly|
|Aaron Schwartz, Novo Nordisk|
|Riccardo Perfetti, Sanofi Diabetes & Cardiovascular Business Unit|
|Nandan Padukone, Joslin Diabetes Center|
|Thomas Seoh, Kinexum|
|Jonathan Behr, JDRF|
|Nathaniel Heintzman, Dexcom|
|Vivek Shenoy, Renovo Neural|
|Judith Gorski, Crown Bioscience|
|Vijay Koya, Boston Scientific|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
BioSpherix will be exhibiting the Xvivo System, world's first and only cytocentric barrier isolator optimized for cells. Economical and practical alternative to cleanrooms for cGMP compliant production of cells for clinical use. Get better contamination, process and quality control. Stop by BioSpherix booth to learn more about the only total quality platform for cells!
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.
Merck has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. We're pursuing some of the most innovative areas in biomedical research emerging today without regard to therapeutic area/modality. Merck has hundreds of successful collaborations with companies, academic institutions, and other organizations. Learn more at www.merck.com/licensing.
CBSET is a not-for-profit translational research institute specializing in the evaluation of drugs, biotherapeutics, combination products, and medical devices. We provide preclinical services including in-life testing, histopathology and regulatory consulting. Our GLP-compliant facilities host a multidisciplinary team of medical, scientific and regulatory experts who actively collaborate in getting novel technologies to market.
Mercodia is an immunoassay developer in CVD/Metabolism since 1991. We have research-use and FDA-validated immunoassays that meet stringent criteria for moving a therapeutic from research to clinic. We are the gold standard for measuring glucagon, giving researchers tools necessary to identify associations and causal roles for biomarkers in metabolic disease.